Finding new drugs to treat high-risk rhabdomyosarcoma
High-risk rhabdomyosarcoma patient derived 3D cultures to screen for novel drugs that enhance sensitivity to standard treatment
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Improving our understanding of ependymomas in the spinal cord
Comprehensive molecular characterization of paediatric spinal ependymomas
Using modern scanning techniques to diagnose brain tumours more quickly and accurately
Improving the diagnosis of children’s brain tumours by Functional Radiomics
Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Investigating a newly discovered gene to improve our understanding of Wilms tumour
Epigenetic deregulation of splicing in childhood renal malignancies
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis
Developing a test to help treat leukaemia that has spread to the brain
Developing leukaemic biomarkers to enable personalised CNS-directed therapy